search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Company insight


time to market for new life-saving devices, the new EU MDR will most likely lead to an increase in time to market for medical device companies.


Sustainability driver


Alleima is a one-stop-shop for medical wire processing and a front runner regarding sustainability, according to Dr Cacie McDorman (right) and Lena Wiig Boström.


act of engineering and chemistry, testing even the most experienced design team. “We are a one-stop shop for medical wire processing. We offer a variety of value-added processes to our wire to help customers reduce the need for additional suppliers, and in some cases can provide fully finished devices directly to the customer,” says Dr Cacie McDorman, engineering manager at the product unit in Palm Coast, Florida.


Life-changing partnership The sales and engineering teams at Alleima work closely with their customers to anticipate the next move and to be forward- thinking. There are several examples over the years where customers have said they hoped they had met the engineering team from Alleima earlier in their design process


because that would have saved them considerable time to market. “Our engineers are not afraid of the impossible,” McDorman continues. “We have helped various customers achieve their end product when others could not. We are always looking for new ways to reduce the footprint of a device or integrate additional features into devices, whether that be through the use of new alloys, coatings or manufacturing processes. We have knowledge of industry trends and the needs of patients and physicians, and try to advance our capabilities and offerings to meet these needs.”


Also appreciated is Alleima’s support to customers in overcoming regulatory hurdles by partnering with them throughout the approval process. While the FDA has implemented ways to reduce the


Alleima is a sustainability frontrunner, with ambitious goals for the future. Sustainability is present in all aspects of the company’s operations and an integral part of its commercial strategy. The use of recycled material and more than 96% fossil-free electricity at its production sites, reducing water usage, and careful chemical management are a few of the actions that have been implemented. The fully integrated value chain, from R&D and melting to end-product enables Alleima to provide sustainability and circularity in all its operations.


It has also committed to the Science- Based Targets initiative (SBTi), which is a partnership between the Carbon Disclosure Project (CDP), the United Nations Global Compact, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF). The company sees this engagement as an opportunity to add credibility, clarify the ambition of its customers, and enable it to work with its supply chain to address its carbon footprint. Organisations with science-based targets have demonstrated that they are leading the way by significantly cutting emissions. “To advance industries, first we must advance ourselves. Our ambitious goals keep us looking and thinking ever forward. Our long-term sustainability targets reflect our commitment to be at the forefront of sustainability”, says Lena Wiig Boström, marketing communications manager at Alleima Business Unit Medical. In its partnerships with the SBTi, Alleima will develop a targeted proposal that will undergo technical validation before it can be publicly launched. The SBTi allows a maximum period of 24 months between commitment and approved targets. Alleima is already a signatory to several international principles and initiatives, including the UN’s global goals for sustainable development and the United Nations Global Compact. Setting goals and making progress transparent to partners and customers is an important part of the strategy. ●


Processing nitinol is one core capability of Alleima at their facility in Karlsruhe, Germany. Medical Device Developments / www.nsmedicaldevices.com www.alleima.com/medicalwire 99


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136